Pathophysiology, Evaluation and Management of Valvular Heart Diseases

Developed from “Valves in the Heart of the Big Apple: Evaluation and Management of Valvular Heart Diseases” May 10–12, 2001, New York, N.Y.

A Conference Organized by The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University

Volume Editors

Jeffrey S. Borer New York, N.Y.
O. Wayne Isom New York, N.Y.

58 figures and 43 tables, 2002
Contents

IX Introduction

Epidemiology and Pathophysiology

1 The Epidemiology of Valvular Heart Disease: An Emerging Public Health Problem
   Supino, P.G.; Borer, J.S.; Yin, A. (New York, N.Y.)

7 The Cellular and Molecular Basis of Heart Failure in Regurgitant Valvular Diseases: The Myocardial Extracellular Matrix as a Building Block for Future Therapy

15 Emerging Biology of Mitral Regurgitation: Implications for Further Therapy
   Starling, M.R. (Ann Arbor, Mich.)

25 Aortic Valve Disease – Etiology and the Role of Vascular Pathology: Is the Face of the Disease Changing?
   Fuster, V.; Rosenbluth, A. (New York, N.Y.)

39 Atrial Fibrillation and Valve Disease
   Somberg, J.; Molnar, J. (Chicago, Ill.)

Aortic Valve Diseases

49 Selection of Patients with Aortic Stenosis for Operation: The Asymptomatic Patient and the Patient with Poor LV Function
   Carabello, B.A. (Houston, Tex.)
The Value of Myocardial Perfusion Imaging for Diagnosing Coronary Artery Disease in Patients with Aortic Valve Stenosis
Van Tosh, A. (New York, N.Y.)

Congenital Aortic Stenosis: Is Repair an Option?
Lamberti, J.J. (New York, N.Y.)

Aortic Regurgitation: Selection of Asymptomatic Patients for Valve Surgery

Surgical Approaches When Aortic Regurgitation Is Associated with Aortic Root Disease
Girardi, L.N. (New York, N.Y.)

Technique and Results of the Modified Ross Procedure in Aortic Regurgitation versus Aortic Stenosis
Stelzer, P. (New York, N.Y.)

Percutaneous Mitral Balloon Valvuloplasty. Does It Really Last as Long and Do as Well as Surgery?
Palacios, I.F. (Boston, Mass.)

Mitral Commissurotomy and Valve Replacement for Mitral Stenosis: Observations on Selection of Surgical Procedures
Isom, O.W. (New York, N.Y.)

Mitral Regurgitation: Natural History in Operated and Unoperated Patients

Complications of Mitral Valve Prolapse
Jeresaty, R.M. (Hartford, Conn.)

Mitral Regurgitation: Predictors of Outcome and Natural History
Enriquez-Sarano, M.; Nkomo, V.; Mohty, D.; Avierinos, J.-F.; Chaliki, H. (Rochester, Minn.)

Importance of Right Ventricular Performance Measurement in Selecting Asymptomatic Patients with Mitral Regurgitation for Valve Surgery

Mitral Valve Repair for Ischemic Mitral Regurgitation
Cohn, L.H. (Boston, Mass.)
157 Concomitant Mitral Repair at the Time of Coronary Artery Bypass Grafting – The ‘Con’ Point of View
Tittle, S.L.; Tolis, G.; Elefteriades, J.A. (New Haven, Conn.)

164 Minimally Invasive Valve Surgery: Evolution of Technique and Clinical Results
Sharony, R.; Grossi, E.A.; Ribakove, G.H.; Ursomanno, P.; Colvin, S.B.; Galloway, A.C. (New York, N.Y.)

Surgical Considerations and Infective Endocarditis

173 Blood Conservation: Is it Working?
Krieger, K.H. (New York, N.Y.)

184 Emerging Role of Complementary Medicine in Valvular Surgery
Oz, M. (New York, N.Y.)

189 Factors Determining Selection of Valve Prosthesis – Tissue or Mechanical: Current Status
Chatterjee, S.; Gardner, T.J. (Philadelphia, Pa.)

195 Selective Aspects of Infective Endocarditis: Considerations on Diagnosis, Risk Factors, Treatment and Prophylaxis
Hartman, B.J. (New York, N.Y.)

203 Echocardiographic Assessment of the Vegetation: Are There Characteristics that Mandate Prophylactic Surgical Intervention?
Berger, M. (New York, N.Y.)

210 Author Index

211 Subject Index
Introduction

Diseased heart valves are a growing public health concern. As death due to coronary artery disease and to non-cardiac causes has been shifted to increasingly older age groups or partially eliminated, valvular diseases have been recognized as common and progressive concomitants of aging. This is particularly true in the USA, Canada and Western Europe, where the prevalence of acquired rheumatic valvular diseases in the first three decades of life has diminished markedly compared with 50 or more years ago. However, the increasing prevalence of valvular diseases also is apparent in other parts of the world, where rheumatic fever remains a very important problem. In addition, modern diagnostic modalities and epidemiological research have led to increasing recognition of the impact of hereditary metabolic predispositions, nonfatal coronary/ischemic events and progression of congenital lesions that are clinically inapparent at birth on the total burden of valvular diseases in the aging population. The result is a growing expenditure of healthcare resources for managing clinical sequelae of dysfunctional heart valves. Consequently, recurring examination is appropriate to define current knowledge of valvular disease pathophysiology, epidemiology, natural history and management strategies. This volume represents one such examination.

More than 25 years ago, at separate institutions, we began research in valvular diseases in conjunction with management of patients with these disorders. Over the course of more than a quarter century of our own experience and that of colleagues throughout the world, it has become increasingly clear that the pathophysiology of valvular diseases varies widely with the affected valve, the specific hemodynamic characteristics of the lesion and the nature of any
associated cardiovascular pathology and that, consequently, each major valve
disease category requires individualized attention both from researchers and
from clinicians. At Weill Medical College of Cornell University, our joint
efforts in exploring concepts and evaluating patients with heart valve diseases
ultimately led to the creation of The Howard Gilman Institute for Valvular Heart
Diseases. The Institute has allowed us to focus intensively on the pathophysiol-
ogy and management of valvular diseases in an environment characterized by
progressively increasing prevalence and complexity of these diseases. The con-
ference entitled, ‘Valves in the Heart of the Big Apple: Evaluation and
Management of Valvular Heart Diseases’, organized by the Institute and jointly
sponsored by The Weill Medical College of Cornell University and The New
York Cardiological Society of the American College of Cardiology, New York
State Chapter, represents one manifestation of that focus. This publication is
drawn from the presentations of several faculty members who participated in the
first convocation of that conference, on May 10–12, 2001. The articles were pre-
pared and updated after the conference to provide succinct statements of impor-
tant contemporary concepts and concerns. In addition to relating current
thinking about appropriate timing of surgery for patients with various valve
lesions (always a moving target as evaluation strategies become more precise and
therapies become more effective and safe), sections of this volume discuss spe-
cific technical issues regarding evolving surgical approaches and selected
pathophysiological considerations at the systemic, whole organ, cellular and
molecular levels. The latter two areas increasingly are appropriate and timely
foci of investigation as the cardiology/ cardiac surgery community works toward
meaningful enhancement of prognostic strategies and development of novel
pharmacotherapy, and even molecular therapy, to beneficially alter the most
fundamental pathophysiology of these diseases before, during and after surgery.

We would like to thank the faculty members that produced the articles for
this volume and to acknowledge that each of them was importantly involved, by
virtue of his or her own research, in creating the new knowledge about which each
has written. In addition, we would like to thank The Howard Gilman Foundation,
which supports much of the research at our Institute and which enabled organi-
zation of ‘Valves in the Heart of the Big Apple’ and this volume, Johnson &
Johnson, Inc., which provided a much appreciated unrestricted educational grant
enabling preparation of articles for this publication, and the Howard L. and
Judie Ganek Philanthropic Fund of the Jewish Communal Fund, which provided
an unrestricted grant to cover publication costs. Our appreciation also extends to
the providers of unrestricted educational support for the conference: in addition
to our primary benefactor, Johnson & Johnson, Inc., these included Edwards
Life Science, American Home Products-Wyeth-Ayerst Laboratories, Medtronic,
Otsuka America Pharmaceutical, Inc., St. Jude Medical, Sulzer Carbomedics/
Scanlon Cardiopulmonary, Pfizer, Inc., Astra Zeneca Pharmaceuticals, Sankyo Pharma, and Pfizer.

We believe this volume represents a useful adjunct for clinician and researcher. We hope readers will agree.

Jeffrey S. Borer, MD
O. Wayne Isom, MD